trending Market Intelligence /marketintelligence/en/news-insights/trending/av2sssfxlselr3pg8gvpzw2 content esgSubNav
In This List

Stallergenes Greer anti-allergy drug receives expanded approval in Japan

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Stallergenes Greer anti-allergy drug receives expanded approval in Japan

U.K.-based pharmaceuticals company Stallergenes Greer PLC has secured expanded approval for its anti-allergy drug Actair in Japan for use in pediatric patients.

Actair is an allergy immunotherapy already approved to treat house dust mite for patients older than 12 years of age or older in Japan. The expansion allows children ages five to 11 to be treated.

The approval was supported by the results a phase 3 study in which the drug statistically demonstrated a reduction in disease symptoms over the course of a year compared to placebo.

The drug is a joint venture between Stallergenes and Japan's pharmaceuticals giant Shionogi & Co. Ltd.